Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling

The aim of this research was to differentiate dapagliflozin, empagliflozin, and canagliflozin based on their capacity to inhibit sodium‐glucose cotransporter (SGLT) 1 and 2 in patients with type 2 diabetes using a previously developed quantitative systems pharmacology model of renal glucose filtrati...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:CPT Pharmacometrics Syst Pharmacol
Autors principals: Sokolov, Victor, Yakovleva, Tatiana, Chu, Lulu, Tang, Weifeng, Greasley, Peter J., Johansson, Susanne, Peskov, Kirill, Helmlinger, Gabriel, Boulton, David W., Penland, Robert C.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7180004/
https://ncbi.nlm.nih.gov/pubmed/32064793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12498
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars